In the presence of PR agonists, such as progesterone (P4) or progestins, PR associates with ER and directs ER chromatin binding events within breast cancer cells, resulting in a gene expression signature that is associated with a good clinical outcome [78]. Here, ESR1 is linked to breast carcinoma.